Therma Bright Inc V.THRM

Min valuation for Therma once product available at least 10x

[magnuswave]

Comparing Medmira which has basically no sales of any relevance carries a market cap of $154 mln based on a current price of 25 cents.  The market is willing to give Mir this market cap based on potential.   If we apply the same market cap to thrm once product available we should expect at least 70 to 80 cents.  This is how we should be looking at THRM as a spec paly rather than picking baseless numbers.  The collective market particpants will re- rate once a product available which may only be a few weeks away.  Below are the latest #'s and they are not anything to get excited about so the question should be is MIR overpriced or THRM underpriced.  Split the differnece and you still should get 40 to 50 cents for THRM.  

MedMira Reports Third Quarter Results FY2020

 

Email Print Friendly Share

June 29, 2020 20:00 ET  | Source: MedMira Inc.

 

 

HALIFAX, Nova Scotia, June 29, 2020 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended April 30, 2020. 

Important Notice

The Company’s Q3 FY2020 statements have recorded all financial transactions from the 1^st of February 2020 until the 30^th of April 2020. Any subsequent transactions after the end of the third quarter are not recorded in the Company’s financial statement and balance sheet for Q3 FY2020.

Profit and Loss Highlights

• Revenue: The Company recorded revenues in Q3 FY2020 of $87,207 compared to $143,387 in Q3 FY2019. The decrease of these revenues was due to the delay of orders received due to the COVID-19 worldwide situation.
• Gross Profit: The Company recorded a gross profit in Q3 FY2020 of $70,344 compared to $119,980 for the same period last year. The overall gross margin percentage on sales was 81% compared to a gross margin of 84% in the same quarter last financial year.
• Operating expenses: The Company recorded for this quarter operating expenses of $602,996 compared to $429,205 in Q3 FY2019. The increase of 40% in operating expenses was primarily due to the volatile exchange rates for USD/CAD$ and CHF/CAD$ in the month of March 2020.
• Net loss: The Company recorded a net loss of $692,479 compared to $512,558 in Q3 FY2019. The increase is mainly due to the additional costs for the product development of REVEALCOVID-19 Total Antibody Test and the overall world wide economical situation created by COVID-19.

[Patienceiskee]

Hate to make you sound stupid but if you're going to compare on this forum another company like Med Mira which I actually own a good portion of shares there to at least the akhrat you say that their market cap is only on potential they already have being selling multiple test kits for multiple viruses and diseases for years and selling them worldwide so get your story straight. Are we buy your

[magnuswave]

Hate to point out you should use spell check to help decipher your reply which sounds like jibberish so hate to make you look stupid but it is what it is.  Makes no sense.  What I can tell you is all the years of MIR selling other product amounted to next to nothing as well in terms of sales and the market cap was much lower prior to launching a covid product.  The sales numbers don

[Patienceiskee]

Either way I bought more of Med mirror yesterday a lot more and made money today and I'll buy more shares here when we go down to $0.05 gibberish or not